VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company’s flagship immunotherapy, at the Centrum Onkologii – Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU. Currently, the study is actively recruiting patients in the United States and India as well. The Company expects to enroll approximately 85 patients at five clinical sites in Poland. The total study is expected to enroll about 880 head and neck cancer patients in about 48 hospitals in 9 countries on three continents. CEL-SCI’s partners Teva Pharmaceuticals and Orient Europharma will conduct parts of the Phase III study in Israel and Taiwan respectively.
